The SIRIAM Neurodermal Atlas

The SIRIAM Neurodermal Atlas provides a concise overview of the regional architecture of the platform.

It translates the general principles established in the preceding chapters into a continuous regional system extending from the cranio-cervical junction to the sacrococcygeal region.

The atlas does not repeat the complete theoretical basis of:

Ingredient Design Strategy.

These principles apply to the entire platform and are described in their respective chapters.

The present chapter focuses exclusively on:

platform position.

• Segment Prioritization;
• Metameric Foundation;
• Neurodermal Application Architecture;
• DUO;
• Functional Matrix;
• Vehicle Architecture;
• Structural Matrix;
• regional identity;
• metameric orientation;
• primary Application Fields;
• principal Neurodermal Application Zones;
• regional continuity;

Each atlas fiche contains the same concise elements:

Anatomical references and SIRIAM Conceptual Models remain distinguished according to the evidence convention established earlier in the Handbook.

The regional SIRIAM system is organized as an overlapping neurodermal axis:

OAA

↓

PHRENIC

↓

PLEXUS BRACHIALIS / CTO

↓

PLEXUS SOLARIS

↓

TLO

↓

PLEXUS LUMBALIS

↓

PLEXUS LUMBOSACRALIS

↓

SX

This sequence is not intended to represent isolated compartments.

Neighbouring fields overlap intentionally in order to preserve anatomical and application continuity.

KORR Integralis and InflammaSacra occupy separate positions within the platform:

Regional Metameric Recovery System

+

KORR Segmental Runner

+

InflammaSacra Symptom-Support System

ATLAS FICHE 16-A

OAA

Product identity

OAA — Occipito-Atlanto-Axial Application Field

Platform classification

Regional Metameric Recovery System

Metameric orientation

Cranio-cervical junction, principally C0–C2.

Primary Application Field

Occipito-Atlanto-Axial Complex.

Principal Neurodermal Application Zones

Suboccipital

Retroauricular

Submandibular

Pre-SCM

Anatomical orientation

The OAA Application Field includes the upper cervical and cranio-cervical transition.

Relevant structures within the field include:

superficial branches associated with the upper cervical plexus.

The submandibular zone may include the cutaneous territory related to mandibular and mylohyoid-associated structures.

The Pre-SCM zone includes the regional relationship with:

cervical branch of the facial nerve.

Regional identity

Cranial Gateway

OAA represents the superior entry point of the SIRIAM neurodermal axis.

Regional continuity

Primary continuation toward:

CTO.

Functional architecture

DUO:

OAA Release

↓

OAA Integration

↓

Maintenance

SIRIAM Conceptual Model

OAA is conceptualized as a cranio-cervical integration field linking the upper cervical neurodermal interface with the superior boundary of the metameric recovery platform.

Embryological references to hindbrain and cranio-cervical development are treated as conceptual orientation and not as evidence of direct influence on central nervous-system nuclei.

Current development status

final Master Formula not yet released.

ATLAS FICHE 16-B

PHRENIC

Product identity

PHRENIC — Anterior Cervical Application Field

Platform classification

Regional Metameric Recovery System

Metameric orientation

Principally C3–C5.

Primary Application Field

Anterior Cervical and Cervico-Respiratory Transition.

Principal Neurodermal Application Zones

The final standardized NAZ boundaries remain to be consolidated in the dedicated Application Field fiche.

Current regional orientation includes:

superior thoracic continuation where clinically indicated.

Anatomical orientation

The Phrenic Application Field is organized around the cervical segmental region associated with C3–C5 and the anterior cervical tissues through which the phrenic nerve descends.

Topical application does not imply direct access to or modulation of the phrenic nerve itself.

Regional identity

Cervico-Respiratory Bridge

Phrenic represents the anterior transition between the cranio-cervical region and the upper thoracic platform.

Regional continuity

Overlaps intentionally with:

CTO.

Functional architecture

DUO:

PHRENIC Release

↓

PHRENIC Integration

↓

Maintenance

SIRIAM Conceptual Model

Phrenic is positioned as an anterior cervical neurodermal field within the broader regional architecture.

Current development status

final Master Formula not yet released.

ATLAS FICHE 16-C

PLEXUS BRACHIALIS

Product identity

PLEXUS BRACHIALIS — Cervico-Brachial Application Field

Platform classification

Regional Metameric Recovery System

Metameric orientation

Principally C5–T1, with emphasis on C6–C8 according to Segment Prioritization.

Primary Application Field

Cervico-Brachial Transition and Upper-Limb Neurodermal Extension.

Principal Neurodermal Application Zones

The final standardized field may include:

ulnar upper-limb trajectory.

The exact number and boundaries of the final NAZ remain subject to clinical and anatomical consolidation.

Anatomical orientation

The Application Field follows the regional relationship between:

peripheral trajectories associated with radial, median and ulnar distributions.

The formulation is not presented as a direct treatment of individual peripheral nerves.

Regional identity

Spinal-to-Peripheral Interface

Plexus Brachialis extends the metameric platform from the cervical spine toward the upper extremity.

Regional continuity

Overlaps with:

upper-limb application trajectories.

Functional architecture

DUO:

PLEXUS BRACHIALIS Release

↓

PLEXUS BRACHIALIS Integration

↓

Maintenance

SIRIAM Conceptual Model

The field is designed to connect segmental prioritization with a broader cervico-brachial neurodermal application strategy.

Current development status

final Master Formula not yet released.

ATLAS FICHE 16-D

CTO

Product identity

CTO — Cervico-Thoracic Application Field

Platform classification

Regional Metameric Recovery System

Metameric orientation

Lower cervical and upper thoracic transition, principally around C8–T1 and adjacent segments.

Primary Application Field

Cervico-Thoracic Junction.

Principal Neurodermal Application Zones

The current regional architecture includes:

regional lateral extension where indicated.

Final NAZ boundaries remain to be represented in the dedicated anatomical application figure.

Anatomical orientation

The field includes the transition between:

shoulder-girdle and cervico-thoracic fascial interfaces.

Regional identity

Cervico-Thoracic Bridge

CTO provides continuity between the cervical platform and the thoracic trunk architecture.

Regional continuity

Overlaps with:

Plexus Solaris.

Functional architecture

DUO:

CTO Release

↓

CTO Integration

↓

Maintenance

Current development status

final Master Formula not yet released.

ATLAS FICHE 16-E

PLEXUS SOLARIS

Product identity

PLEXUS SOLARIS — Upper Abdominal Application Field

Platform classification

Regional Metameric Recovery System

Metameric orientation

Principally T5–T9.

Primary Application Field

Upper Abdominal and Epigastric Neurodermal Field.

Principal Neurodermal Application Zones

Current orientation includes:

corresponding thoracic paraspinal field.

Exact NAZ boundaries remain to be standardized visually.

Anatomical orientation

The Application Field includes the regional relationship between:

posterior thoracic segmental field.

The term “Plexus Solaris” describes the regional application architecture and does not imply that a topical product directly reaches the coeliac plexus.

Regional identity

Central Trunk Integration Field

Plexus Solaris forms the central upper-abdominal interface of the SIRIAM platform.

Regional continuity

Overlaps with:

TLO.

Functional architecture

DUO:

PLEXUS SOLARIS Release

↓

PLEXUS SOLARIS Integration

↓

Maintenance

SIRIAM Conceptual Model

Plexus Solaris is conceptualized as a central neurodermal field connecting posterior thoracic prioritization with anterior upper-abdominal application.

Current development status

final Master Formula not yet released.

ATLAS FICHE 16-F

TLO

Product identity

TLO — Thoraco-Lumbar Application Field

Platform classification

Regional Metameric Recovery System

Metameric orientation

Principally T10–L2.

Primary Application Field

Thoraco-Lumbar Junction.

Principal Neurodermal Application Zones

Current orientation includes:

corresponding lateral or anterior transition where clinically indicated.

Final NAZ boundaries remain to be standardized in the application map.

Anatomical orientation

The TLO field includes the transition between:

related posterior and posterolateral tissues.

Regional identity

Thoraco-Lumbar Bridge

TLO connects thoracic trunk architecture with the lumbar and pelvic platform.

Regional continuity

Overlaps with:

upper component of Plexus Lumbosacralis where relevant.

Functional architecture

DUO:

TLO Release

↓

TLO Integration

↓

Maintenance

Current development status

final Master Formula not yet released.

ATLAS FICHE 16-G

PLEXUS LUMBALIS

Product identity

PLEXUS LUMBALIS — Lumbar Application Field

Platform classification

Regional Metameric Recovery System

Metameric orientation

Principally L1–L4.

Primary Application Field

Lumbar Neurodermal and Lumbo-Femoral Transition.

Principal Neurodermal Application Zones

Current orientation may include:

proximal anterior or medial thigh trajectory.

Exact zones remain to be finalized in the dedicated anatomical application protocol.

Anatomical orientation

The field relates regionally to:

proximal lower-extremity trajectories.

The topical field does not imply direct delivery to the deep lumbar plexus.

Regional identity

Lumbar-to-Lower-Limb Interface

Plexus Lumbalis extends the regional architecture from the lumbar spine toward the anterior and medial lower extremity.

Regional continuity

Overlaps with:

lower-limb regional trajectories.

Functional architecture

DUO:

PLEXUS LUMBALIS Release

↓

PLEXUS LUMBALIS Integration

↓

Maintenance

Current development status

final NAZ boundaries and Master Formula not yet released.

ATLAS FICHE 16-H

PLEXUS LUMBOSACRALIS

Product identity

PLEXUS LUMBOSACRALIS — Lumbo-Sacral Application Field

Platform classification

Regional Metameric Recovery System

Metameric orientation

Principally L4–S2, with regional extension according to prioritized lower sacral components.

Primary Application Field

Lumbo-Sacral and Pelvic-Lower-Limb Transition.

Principal Neurodermal Application Zones

Current orientation may include:

posterior or lateral lower-limb trajectory.

Final standardized boundaries remain to be established.

Anatomical orientation

The regional field relates to:

pelvic and proximal posterior lower-limb tissues.

Regional identity

Lumbo-Sacral Distribution Field

Plexus Lumbosacralis forms the principal transition between the lumbar and sacral systems and their lower-limb extensions.

Regional continuity

Overlaps with:

SX.

Functional architecture

DUO:

PLEXUS LUMBOSACRALIS Release

↓

PLEXUS LUMBOSACRALIS Integration

↓

Maintenance

Current development status

final Master Formula not yet released.

ATLAS FICHE 16-I

SX

Product identity

SX — Sacral Application Field

Platform classification

Regional Metameric Recovery System

Metameric orientation

Sacral and sacrococcygeal region, principally S1–S5 with caudal continuation.

Primary Application Field

Sacral Neurodermal Field.

Principal Neurodermal Application Zones

Current orientation includes:

regional pelvic extension where clinically indicated.

Final application boundaries require graphical standardization.

Anatomical orientation

The SX Application Field includes:

inferior boundary of the spinal regional platform.

Regional identity

Caudal Integration Field

SX represents the inferior completion of the SIRIAM neurodermal axis.

OAA and SX form the superior and inferior polar regions of the platform.

Regional continuity

Overlaps with:

lower pelvic Application Fields.

Functional architecture

DUO:

SX Release

↓

SX Integration

↓

Maintenance

Current development status

final Master Formula not yet released.

ATLAS FICHE 16-J

KORR INTEGRALIS

Product identity

KORR Integralis — Segmental Runner

Platform classification

Segmental Support System.

KORR is not a regional DUO formulation.

Segmental orientation

One isolated prioritized dermatome, spinal level or limited segmental field.

Primary Application Field

No fixed regional Application Field.

The application location is determined by individual Segment Prioritization.

Principal Neurodermal Application Zones

The NAZ corresponds to the selected segmental or dermatomal application trajectory.

Regional identity

Neutral Segmental Runner

KORR is intended for focused application when one segment or dermatome is more strongly prioritized than the surrounding regional field.

Platform relationship

KORR:

may be used independently or alongside a regional strategy according to the application protocol.

Functional architecture

KORR does not automatically follow the complete regional DUO architecture.

Its functional use is determined by the specific segmental indication within the SIRIAM framework.

Formulation requirement

The formulation should remain sufficiently neutral to avoid assuming the identity of a specific regional field.

The current formula requires further tightening, including:

optimal viscosity for 15 ml airless dispensing.

Current development status

professional review by Anouck Van Aerschot required.

ATLAS FICHE 16-K

INFLAMMASACRA

Product identity

InflammaSacra — Symptom- and Phase-Oriented Support System

Platform classification

Horizontal Support Line.

InflammaSacra is not part of the regional metameric coverage system.

Primary purpose

Support within symptom-oriented pain and inflammatory presentations.

This purpose remains distinct from regional Segment Prioritization.

Application architecture

InflammaSacra follows a three-phase sequence:

InflammaSacra I

↓

InflammaSacra II

↓

InflammaSacra III

The phases reflect progression over time and clinical context rather than the regional Release–Integration DUO.

Regional identity

InflammaSacra has no exclusive regional identity.

It may be applied in relation to a symptomatic Application Field according to the relevant protocol.

Platform relationship

InflammaSacra may accompany:

another clinically selected application strategy.

It does not replace the regional system.

Current development status

final phase-specific Master Formulae not yet released.

• suboccipital tissues;
• upper cervical cutaneous and myofascial structures;
• retroauricular region;
• submandibular neurodermal interface;
• anterior border region of the sternocleidomastoid muscle;
• great auricular nerve;
• transverse cervical nerve;
• platysma;
• Phrenic;
• upper cervical components of Plexus Brachialis;
• Multiple formulation generations completed;
• current development formulation available;
• pharmaceutical rebuilding and viscosity optimization planned;
• regional EMG evaluation initiated or planned;
• anterolateral cervical field;
• regional projection along the sternocleidomastoid area;
• lower anterior cervical transition;
• OAA;
• Plexus Brachialis;
• current prototype formulation available;
• pharmaceutical rebuilding planned;
• exact NAZ map to be finalized;
• clinical and technical evaluation ongoing;
• lower cervical and supraclavicular transition;
• shoulder-girdle field;
• medial upper-limb trajectory;
• radial upper-limb trajectory;
• cervical roots;
• brachial plexus projection;
• shoulder girdle;
• proximal upper limb;
• Phrenic;
• CTO;
• DUO formulation developed;
• regional differences identified;
• pharmaceutical refinement planned;
• anatomical application map requires final graphic standardization;
• lower cervical transition;
• cervico-thoracic junction;
• upper thoracic paraspinal field;
• lower cervical spine;
• first thoracic segments;
• upper thoracic paraspinal tissues;
• Phrenic;
• Plexus Brachialis;
• current DUO formulation available;
• regional signature established;
• pharmaceutical rebuilding and airless optimization planned;
• epigastric field;
• lower sternal transition;
• upper abdominal central field;
• mid-thoracic segments;
• epigastric skin and fascia;
• upper abdominal wall;
• CTO;
• DUO formulation developed;
• regional signature ingredients identified;
• pilot EMG work previously performed in the regional field;
• new pharmaceutical preparation and clinical evaluation planned;
• lower thoracic paraspinal field;
• thoraco-lumbar junction;
• upper lumbar field;
• lower thoracic segments;
• thoraco-lumbar junction;
• upper lumbar segments;
• Plexus Solaris;
• Plexus Lumbalis;
• current DUO formulation available;
• selected regional EMG evaluation initiated or planned;
• pharmaceutical rebuilding and viscosity optimization planned;
• lumbar paraspinal field;
• lower abdominal or inguinal transition;
• anterior hip field;
• lumbar segments;
• lumbar plexus projection;
• iliopsoas and anterior hip interface;
• TLO;
• Plexus Lumbosacralis;
• DUO formulation available;
• regional application architecture developed;
• pharmaceutical redevelopment planned;
• lower lumbar field;
• lumbosacral junction;
• gluteal or posterior pelvic field;
• lower lumbar segments;
• lumbosacral junction;
• sacral plexus projection;
• Plexus Lumbalis;
• TLO;
• current formulation architecture available;
• regional signature differentiated from Plexus Lumbalis and SX;
• pharmaceutical refinement planned;
• upper sacral field;
• central sacral field;
• lower sacral field;
• sacrococcygeal transition;
• sacral posterior tissues;
• sacrococcygeal transition;
• superficial pelvic neurodermal interfaces;
• Plexus Lumbosacralis;
• DUO formulation available;
• regional formulation identity established;
• pharmaceutical rebuilding planned;
• complements the regional system;
• does not replace a regional DUO when a broader Application Field is indicated;
• exact q.s. ad 100.00 g;
• standardized units;
• Cosgard inclusion;
• definitive water-phase quantity;
• definitive jojoba concentration;
• assessment of Rhodiola within the neutral-runner concept;
• development formulation available;
• not yet a finalized Master Formula;
• complete pharmaceutical reconstruction planned;
• a regional DUO formulation;
• KORR;
• three-phase system developed;
• current magistrale formulations available;
• pharmaceutical rebuilding and harmonization planned;

The listed segmental ranges are principal orientations and should not be interpreted as rigid, non-overlapping boundaries.

The present atlas describes the current regional architecture of the SIRIAM Platform.

It is based on:

ongoing pharmaceutical optimization.

The current products represent development formulations and not yet final validated Master Formulae.

During the next development cycle:

only thereafter will substantive compositional revisions be considered.

Professional Review Notes — Chapter 16

Anouck Van Aerschot

These notes apply to the atlas as a whole and are intentionally not repeated in every regional fiche.

PR-16.1 Product identity

☐ Confirm that each magistrale fiche uses the same official product name as the atlas.

☐ Correct differences in spelling, abbreviation or phase designation.

PR-16.2 Formulation classification

☐ Confirm which products follow DUO.

☐ Confirm KORR as a separate segmental formulation.

☐ Confirm InflammaSacra as a separate three-phase support system.

PR-16.3 Packaging

☐ Confirm compatibility of each formulation with the intended 15 ml airless dispenser.

☐ Register any formulation requiring a different viscosity or filling procedure.

PR-16.4 Production observations

For every product:

☐ leave unresolved points open for later review.

PR-16.5 Master Formula status

☐ Do not classify the current fiches as final Master Formulae.

☐ Release Master Formula status only after pharmaceutical and subsequent development review.

Editor’s R&D Note — Chapter 16

The atlas deliberately avoids detailed ingredient lists and repeated theoretical explanations.

Regional identity is documented here.

Ingredient logic will be organized comparatively in:

Chapter 17 — Regional Signature Design

Chapter 18 — Platform Ingredient Atlas

Chapter 19 — Regional Signature Ingredients

• successive formulation generations;
• anatomical and segmental design;
• practical clinical development;
• observed application patterns;
• early regional EMG pilot work;
• the existing fiches will be used as the basis for production;
• Anouck Van Aerschot will review and prepare the formulations;
• technically necessary production adjustments may be incorporated immediately into cleaned magistrale development versions;
• the new batches will be evaluated in clinical use;
• selected products may be evaluated using standardized pre- and post-application EMG;
• wider spinal EMG protocols may be investigated using the new measurement system;
• ☐ document changes required during preparation;
• ☐ record exact changes in grams;
• ☐ specify whether the change is technical or conceptually relevant;
• ☐ transfer accepted changes to the cleaned development fiche;